- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00849810
Comparing the Effects of Two Beta Blockers,Metoprolol and Nebivolol,on Ambulatory Blood Pressure and Basal Metabolic Rate
March 18, 2013 updated by: Deborah Minor, University of Mississippi Medical Center
Comparative Effects of Nebivolol Versus Metoprolol on 24-hour Blood Pressures and Basal Metabolic Rate: An Open-Label Study
The purpose of the study is to compare the effects of nebivolol and metoprolol on 24-hour ambulatory blood pressure characteristics and basal metabolic rates in patients with hypertension.
Study Overview
Study Type
Interventional
Enrollment (Actual)
1
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Mississippi
-
Jackson, Mississippi, United States, 39216
- University of Mississippi Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- 18 years old or older
- currently be treated at a University of MS Medical Center Internal Medicine Clinics
- currently taking metoprolol succinate for hypertension
- have their hypertension controlled (<140/90).
Exclusion Criteria:
- uncontrolled hypertension
- severe renal or moderate hepatic impairment
- currently taking CYP 2D6 inducers/inhibitors
- recent stroke (less than 6 months)
- recent myocardial infarction (less than 6 months)
- congestive heart failure
- diagnosed obstructive sleep apnea
- atrial fibrillation
- arm circumference >50 cm
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Metoprolol to nebivolol
metoprolol 25-200mg at a stable daily dose for 4 weeks, then change to nebivolol at a comparable stable dose (5-20 mg) for 4 -5 weeks.
|
Metoprolol tablets 25-200 mg daily times four weeks.
Nebivolol daily for 4-5 weeks
Other Names:
5 - 20 mg daily, at a stable dose for 4 to 5 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Primary Outcome is Pre- and Post-treatment Ambulatory Blood Pressure.
Time Frame: 4 weeks (pre- and post-treatment)
|
4 weeks (pre- and post-treatment)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Deborah Minor, PharmD, University of Mississippi Medical Center
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2009
Primary Completion (ACTUAL)
November 1, 2010
Study Completion (ACTUAL)
November 1, 2010
Study Registration Dates
First Submitted
February 2, 2009
First Submitted That Met QC Criteria
February 23, 2009
First Posted (ESTIMATE)
February 24, 2009
Study Record Updates
Last Update Posted (ESTIMATE)
March 19, 2013
Last Update Submitted That Met QC Criteria
March 18, 2013
Last Verified
March 1, 2013
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Hypertension
- Physiological Effects of Drugs
- Adrenergic beta-Antagonists
- Adrenergic Antagonists
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Anti-Arrhythmia Agents
- Antihypertensive Agents
- Vasodilator Agents
- Autonomic Agents
- Peripheral Nervous System Agents
- Adrenergic Agonists
- Adrenergic beta-Agonists
- Sympatholytics
- Adrenergic beta-1 Receptor Antagonists
- Adrenergic beta-1 Receptor Agonists
- Nebivolol
- Metoprolol
Other Study ID Numbers
- 2009-0002 (Institutional Review Board)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertension
-
National Taiwan University Hospital Hsin-Chu BranchRecruitingHypertension,Essential | Hypertension, MaskedTaiwan
-
University of Alabama at BirminghamTroy UniversityCompletedHypertension | Hypertension, Resistant to Conventional Therapy | Uncontrolled Hypertension | Hypertension, White CoatUnited States
-
BayerCompletedPrimary HypertensionChina
-
Columbia UniversityAgency for Healthcare Research and Quality (AHRQ)Active, not recruitingWhite Coat Hypertension | Hypertension,EssentialUnited States
-
Addpharma Inc.Completed
-
Universidade Federal de Santa MariaCompletedHealthy Volunteers | Hypertension, EssentialBrazil
-
Sheffield Teaching Hospitals NHS Foundation TrustUniversity of SheffieldCompletedIdiopathic Pulmonary Arterial Hypertension | Chronic Thromboembolic Pulmonary HypertensionUnited Kingdom
-
China Academy of Chinese Medical SciencesGuang'anmen Hospital of China Academy of Chinese Medical SciencesCompletedHypertension, Resistant to Conventional Therapy | Primary HypertensionChina
-
Cytos Biotechnology AGCompletedMild Essential Hypertension | Moderate Essential HypertensionSwitzerland
Clinical Trials on Metoprolol
-
SanionaCompleted
-
University of CincinnatiTerminated
-
AstraZenecaCompletedAcute Myocardial Infarction
-
University of MinnesotaUniversity of Alabama at Birmingham; United States Department of DefenseTerminatedPulmonary Disease, Chronic ObstructiveUnited States
-
East Coast Institute for ResearchCompletedHypertension | Female Sexual DysfunctionUnited States
-
Bright Future Pharmaceuticals Factory O/B Bright...Chinese University of Hong KongUnknown
-
AstraZenecaSt. John's Research InstituteCompletedPrimary HypertensionIndia
-
University of FloridaFood and Drug Administration (FDA)Completed
-
Janssen Research & Development, LLCWithdrawn
-
Harbin Medical UniversityBeijing Chao Yang HospitalCompletedHeart Failure | Anterior Myocardial InfarctionChina